Gianluigi Tanda1. 1. Medication Development Program, Molecular Targets and Medication Discovery Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, 333 Cassell Drive, Triad Bldg., NIDA suite 3301, Baltimore, MD, 21224, USA. gtanda@mail.nih.gov.
Abstract
RATIONALE: The reinforcing effects of most abused drugs have been consistently demonstrated and studied in animal models, although those of marijuana were not, until the demonstration 15 years ago that delta-9-tetrahydrocannabinol (THC) could serve as a reinforcer in self-administration (SA) procedures in squirrel monkeys. Until then, those effects were inferred using indirect assessments. OBJECTIVES: The aim of this manuscript is to review the primary preclinical procedures used to indirectly and directly infer reinforcing effects of cannabinoid drugs. METHODS: Results will be reviewed from studies of cannabinoid discrimination, intracranial self-stimulation (ICSS), conditioned place preference (CPP), as well as change in levels of dopamine assessed in brain areas related to reinforcement, and finally from self-administration procedures. For each procedure, an evaluation will be made of the predictive validity in detecting the potential abuse liability of cannabinoids based on seminal papers, with the addition of selected reports from more recent years especially those from Dr. Goldberg's research group. RESULTS AND CONCLUSIONS: ICSS and CPP do not provide consistent results for the assessment of potential for abuse of cannabinoids. However, drug discrimination and neurochemistry procedures appear to detect potential for abuse of cannabinoids, as well as several novel "designer cannabinoid drugs." Though after 15 years transfer of the self-administration model of marijuana abuse from squirrel monkeys to other species remains somewhat problematic, studies with the former species have substantially advanced the field, and several reports have been published with consistent self-administration of cannabinoid agonists in rodents.
RATIONALE: The reinforcing effects of most abused drugs have been consistently demonstrated and studied in animal models, although those of marijuana were not, until the demonstration 15 years ago that delta-9-tetrahydrocannabinol (THC) could serve as a reinforcer in self-administration (SA) procedures in squirrel monkeys. Until then, those effects were inferred using indirect assessments. OBJECTIVES: The aim of this manuscript is to review the primary preclinical procedures used to indirectly and directly infer reinforcing effects of cannabinoid drugs. METHODS: Results will be reviewed from studies of cannabinoid discrimination, intracranial self-stimulation (ICSS), conditioned place preference (CPP), as well as change in levels of dopamine assessed in brain areas related to reinforcement, and finally from self-administration procedures. For each procedure, an evaluation will be made of the predictive validity in detecting the potential abuse liability of cannabinoids based on seminal papers, with the addition of selected reports from more recent years especially those from Dr. Goldberg's research group. RESULTS AND CONCLUSIONS: ICSS and CPP do not provide consistent results for the assessment of potential for abuse of cannabinoids. However, drug discrimination and neurochemistry procedures appear to detect potential for abuse of cannabinoids, as well as several novel "designer cannabinoid drugs." Though after 15 years transfer of the self-administration model of marijuana abuse from squirrel monkeys to other species remains somewhat problematic, studies with the former species have substantially advanced the field, and several reports have been published with consistent self-administration of cannabinoid agonists in rodents.
Entities:
Keywords:
Addiction; Cannabis; Delta-9-THC; Dopamine neurochemistry; Drug discrimination; Marijuana substance use disorders; Place conditioning; Self-administration; Spice
Authors: Gianluigi Tanda; Su Min Li; Maddalena Mereu; Alexandra M Thomas; Aaron L Ebbs; Lauren E Chun; Valeria Tronci; Jennifer L Green; Mu-Fa Zou; Theresa A Kopajtic; Amy Hauck Newman; Jonathan L Katz Journal: Psychopharmacology (Berl) Date: 2013-04-24 Impact factor: 4.530
Authors: J M Ng Cheong Ton; G A Gerhardt; M Friedemann; A M Etgen; G M Rose; N S Sharpless; E L Gardner Journal: Brain Res Date: 1988-06-07 Impact factor: 3.252
Authors: Bernard Le Foll; Patricia Di Ciano; Leigh V Panlilio; Steven R Goldberg; Roberto Ciccocioppo Journal: Curr Drug Targets Date: 2013-06 Impact factor: 3.465
Authors: Marieka V DeVuono; Kiri L Wills; Danielle V MacPherson; Kelly M Hrelja; Linda A Parker Journal: Psychopharmacology (Berl) Date: 2017-08-12 Impact factor: 4.530
Authors: Robert A Owens; Mohammed A Mustafa; Bogna M Ignatowska-Jankowska; M Imad Damaj; Patrick M Beardsley; Jenny L Wiley; Micah J Niphakis; Benjamin F Cravatt; Aron H Lichtman Journal: Neuropharmacology Date: 2017-06-30 Impact factor: 5.250